Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Patients presenting with Stage III or IV non-Hodgkin's malignant lymphoma were given chemotherapy; about 20% complete remission was obtained for both stages. The addition of radiotherapy increased the incidence to 70% in Stage III patients. The duration of first complete remission was longer for Stage III (25% of the patients are still in first remission at 7 years) than for Stage IV (0%). The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%). Among the new drugs, VM 26 is able to produce a good frequency of remission in patients in relapse.
 ...
PMID:Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. 5 69

Two clusters of patients with Hodgkin's disease are described. The interval between the first contact of the secondary cases with the index cases and the appearance of symptoms suggested a maximum "incubation" period of 2-6 months.
 ...
PMID:"Incubation period" in Hodgkin's disease. 5 75

In a controlled studiy, six patients with stage-IV Hodgkin's disease were given transfer factor (T.F.) prepared from patients with Hodgkin's disease in long remission. There was an apparent increase in cell-mediated immune responses as evidenced by a significant increase in the recipients' lymphocyte responses to phytohaemagglutinin stimulation. Three out of six patients converted to positive delayed-hypersensitivity tests. These three all had the nodular sclerosing type of Hodgkin's disease. These results warrant the further investigation of the use of Hodgkin's disease-specific T.F. as a therapeutic agent in this condition.
 ...
PMID:Transfer factor in Hodgkin's disease. 5 76

A preliminary survey has been carried out to test the feasibility of screening a high-risk group of women for breast cancer, using clinical examination and low-dose mammography, before the establishment of a two-tier screening system of basic well-woman clinics for the over-25s, and breast screening clinics for those over-35s considered to have a higher than average expectation of developing the disease. 7 breast cancers and 1 case of Hodgkin's disease were detected in 618 women (breast cancers 11-3/1000, malignancies 12-9/1000). Though numbers are small they suggest that the women themselves do not suspect the presence of those breast cancers which carry the best prognosis, though being aware of the larger cancers and of many of those benign localised breast lesions requiring surgical treatment.
 ...
PMID:Selective screening for breast cancer in Guildford. 5 84

Thirty-nine patients with advanced Hodgkin's disease (H.D.) resistant to standard combinations of cytotoxic drugs were treated with C.C.N.U., vinblastine and bleomycin (C.V.B.). Ten patients (25%) achieved complete remission (C.R.) and seven of these are still in C.R. at the time of this report. A further 23 patients (59%) achieved partial remissions. The overall response-rate was thus 85%. C.C.N.U. caused less nausea and vomiting than that usually associated with nitrogen mustard. C.C.N.U. and vinblastine caused myelosuppression, but C.V.B. could be administered every 4 weeks to 21 (54%) of the 39 patients. A combination of cytotoxic drugs such as C.V.B. may be preferable to single agents in the treatment of patients with advanced resistant H.D.
 ...
PMID:Combination therapy for advanced resistant Hodgkin's disease. 5 20

Peripheral blood T and B lymphocytes were quantitated in 42 patients with untreated Hodgkin's disease and the results compared with the response to phytohemagglutinin (PHA) stimulation and delayed hypersensitivity skin testing. T lymphocytes were identified by an in vitro cytotoxicity assay employing a specific anti-T-cell serum and by spontaneous rosette formation with sheep erythrocytes (E rosettes). The percentage of T cells in the patients was similar to that of normal subjects as judged by the cytotoxicity assay (65 to 90%). In addition, absolute T-lymphocyte counts were normal in 63% of the patients and were generally reduced only in those with lymphopenia. The percentage of T lymphocytes determined by the E-rosette assay was similar to that determined by the cytotoxicity assay in normal controls, but was significantly lower than that determined by the cytotoxicity assay in the patients. Moreover, the decreased response to PHA stimulation in the patients was directly correlated with the decrease in E-rosette formation. These findings suggest that T lymphocytes in the peripheral blood are not generally diminished in untreated Hodgkin's disease. However, a proportion of these cells exhibits altered surface interactions that may account for some aspects of their impaired immunologic function.
 ...
PMID:Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease. 5 8

This paper reports the preliminary results of a controlled study randomizing MOPP vs. a new four-drug combination (ABVD) in advanced Hodgkin's disease. ABVD consists of 6 cycles of adriamycin, bleomycin, vinblastine, and imidazole carboxamide. The purpose for designing this new combination was two-fold: to compare the efficacy of ABVD with MOPP, and to demonstrate absence of cross-resistance between the two regimens. Of 60 patients entered into the study, 45 (MOPP25, ABVD20) are presently evaluable for the analysis of remission induction. No patient was previously treated with chemotherapy; 20% had relapsed after primary radiotherapy. Whenever possible, complete remission was defined also through rebiopsy of known organ involvement. Complete remission occurred in 76% of patients treated with MOPP and in 75% of those given ABVD, with no difference between the two regimens as far as stage (IIIB-IIIS and IV), histologic type, and prior irradiation were concerned. Crossover carried out for progressive disease or for relapse after initial remission showed absence of cross-resistance between MOPP and ABVD. Toxic manifestations after ABVD were in general well tolerated and reversible. The percent of optimal dose for each drug was as follows: adriamycin 87%, vinblastine 87%, bleomycin 96%, and imidazole carboxamide 96%. These preliminary results indicate that in terms of complete remission, ABVD could represent a successful alternative to MOPP to be used either in MOPP failures or in sequential combination with MOPP. However, the lack of long-term followup limits at the present time an adequate comparison between the two treatments.
 ...
PMID:Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. 5 9

Bone marrow smears of 48 patients consisting of 12 normal cases, 36 patients with different haematological diseases-among them 9 cases of idiopathic thrombopenia, 4 cases of polycythaemia, and 9 cases of Hodgkin's disease - were examined cytochemically. Acid phosphatase, unspecific esterases, naphthol-AS-D-chloroacetate esterase, peroxydase, and leucin-aminopeptidase were represented; in addition the PAS reaction, fastgreen staining at pH 1.1, methyl-green pyronin staining and the lipid representation with Sudan black B were carried out. Besides those responses known from literature the different behaviour of acid megacaryocyte phosphatase in different haematological diseases must be particularly emphasized from all reactions.
 ...
PMID:[Cytochemical studies in megakaryocytes in hematologic diseases]. 5 99

Tumor-seeking radiopharmaceuticals have been employed in the diagnosis of primary neoplasms, in the detection of distant disease, particularly in the localization of tumor foci to facilitate biopsies and the planning of radiation portals, and in assessing the response to tumor therapy. At the present, there is no ideal tumor-scanning agent. However, several approaches appear to be useful and offer promise for further study. The greatest experience has been with Gallium-67, which has major utility in the staging of Hodgkin's disease, in the diagnosis of bronchogenic carcinoma, in the detection of certain metastatic brain tumors, in the identification of recurrent disease, and in the noninvasive diagnosis of leukemic complications. A number of radiolabeled antibiotic and chemotherapeutic agents have shown promise, including tetracycline and bleomycin. A major drawback, however, of these agents which is shared with Gallium-67 is that they appear to be sequestered by inflammatory as well as neoplastic tissue. A most intriguing approach is the use of radiolabeled antibodies to tumor-associated antigens. Animal and clinical experiments have employed antifibrin, antifibrinogen, anticarcinoembryonic antigen, and antiferritin. Theoretically, agents such as these should allow for greater tumor specificity.
 ...
PMID:The radionuclide identification of tumors. 5 2

Increased quantities of the third component of complement (C3) were found in the macromolecular fractions of plasma from patients with untreated Hodgkin's disease (H.D.) These changes provide indirect evidence that immune complexes are present in the plasma of patients with this disease; their presence is closely correlated with the symptoms of night sweats and fever which are associated with a poor prognosis. It is suggested that the detection of circulating complexes may help in assessing the severity of H.D.
 ...
PMID:Circulating immune complexes and symptoms in Hodgkin's disease. 5 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>